These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22159473)

  • 1. Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity.
    Chou MY; Austin CD; Kim JM
    Cancer Immunol Immunother; 2012 Jul; 61(7):1055-64. PubMed ID: 22159473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
    Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
    Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
    Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
    Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
    Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
    J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model.
    Vohra N; Verhaegen M; Martin L; Mackay A; Pilon-Thomas S
    Cancer Immunol Immunother; 2010 May; 59(5):729-36. PubMed ID: 19921187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms.
    von Haehling S; Wolk K; Höflich C; Kunz S; Grünberg BH; Döcke WD; Reineke U; Asadullah K; Sterry W; Volk HD; Sabat R
    Genes Immun; 2015; 16(1):8-14. PubMed ID: 25472783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.
    Nierkens S; den Brok MH; Sutmuller RP; Grauer OM; Bennink E; Morgan ME; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2008 Jul; 68(13):5390-6. PubMed ID: 18593941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
    Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
    Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.